Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 24333591)

1.

Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease.

Bana L, Minniti S, Salvati E, Sesana S, Zambelli V, Cagnotto A, Orlando A, Cazzaniga E, Zwart R, Scheper W, Masserini M, Re F.

Nanomedicine. 2014 Oct;10(7):1583-90. doi: 10.1016/j.nano.2013.12.001. Epub 2013 Dec 10.

PMID:
24333591
2.

Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model.

Salvati E, Re F, Sesana S, Cambianica I, Sancini G, Masserini M, Gregori M.

Int J Nanomedicine. 2013;8:1749-58. doi: 10.2147/IJN.S42783. Epub 2013 May 6.

3.

Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide.

Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, Couraud PO, Moghimi SM, Masserini M, Sancini G.

J Biotechnol. 2010 Dec 20;156(4):341-6. doi: 10.1016/j.jbiotec.2011.06.037. Epub 2011 Jul 6.

PMID:
21763360
4.

Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide.

Taylor M, Moore S, Mourtas S, Niarakis A, Re F, Zona C, La Ferla B, Nicotra F, Masserini M, Antimisiaris SG, Gregori M, Allsop D.

Nanomedicine. 2011 Oct;7(5):541-50. doi: 10.1016/j.nano.2011.06.015. Epub 2011 Jun 29.

PMID:
21722618
5.

Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide.

Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, Sonnino S, Brogioli D, Musicanti C, Gasco P, Salmona M, Masserini ME.

Biomaterials. 2010 Sep;31(25):6519-29. doi: 10.1016/j.biomaterials.2010.04.044.

PMID:
20553982
6.
7.

Abeta20-29 peptide blocking apoE/Abeta interaction reduces full-length Abeta42/40 fibril formation and cytotoxicity in vitro.

Hao J, Zhang W, Zhang P, Liu R, Liu L, Lei G, Su C, Miao J, Li Z.

Neuropeptides. 2010 Aug;44(4):305-13. doi: 10.1016/j.npep.2010.03.001. Epub 2010 Apr 2.

PMID:
20363024
8.

Nanoliposomes presenting on surface a cis-glycofused benzopyran compound display binding affinity and aggregation inhibition ability towards Amyloid β1-42 peptide.

Airoldi C, Mourtas S, Cardona F, Zona C, Sironi E, D'Orazio G, Markoutsa E, Nicotra F, Antimisiaris SG, La Ferla B.

Eur J Med Chem. 2014 Oct 6;85:43-50. doi: 10.1016/j.ejmech.2014.07.085. Epub 2014 Jul 24.

PMID:
25072875
9.

Amyloid binding ligands as Alzheimer's disease therapies.

Lee VM.

Neurobiol Aging. 2002 Nov-Dec;23(6):1039-42. Review.

PMID:
12470800
10.

A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.

Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F.

Neurodegener Dis. 2013;11(1):13-21. Epub 2012 May 8.

PMID:
22572854
12.

Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.

Robert R, Dolezal O, Waddington L, Hattarki MK, Cappai R, Masters CL, Hudson PJ, Wark KL.

Protein Eng Des Sel. 2009 Mar;22(3):199-208. doi: 10.1093/protein/gzn052. Epub 2008 Oct 16.

13.

Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T.

Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18787-92. Epub 2006 Nov 20.

14.
15.

Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.

Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM.

Bioconjug Chem. 2007 Mar-Apr;18(2):447-55. Epub 2007 Feb 22.

16.

The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.

Savelieff MG, DeToma AS, Derrick JS, Lim MH.

Acc Chem Res. 2014 Aug 19;47(8):2475-82. doi: 10.1021/ar500152x. Epub 2014 Jul 31.

PMID:
25080056
18.

K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice.

Zhang YH, Mann D, Raymick J, Sarkar S, Paule MG, Lahiri DK, Dumas M, Bell-Cohen A, Schmued LC.

Curr Alzheimer Res. 2014 Mar;11(3):299-308.

PMID:
24552157
19.
20.

The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue.

Canovi M, Markoutsa E, Lazar AN, Pampalakis G, Clemente C, Re F, Sesana S, Masserini M, Salmona M, Duyckaerts C, Flores O, Gobbi M, Antimisiaris SG.

Biomaterials. 2011 Aug;32(23):5489-97. doi: 10.1016/j.biomaterials.2011.04.020. Epub 2011 May 6.

PMID:
21529932
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk